自然产物（NPs）在开发治疗人类疾病如癌症、代谢性疾病和感染的新型治疗方案方面作出了巨大贡献。与合成化学化合物相比，来自药用植物、真菌、微生物和人体的一次和二次代谢产物是有巨大化学多样性和有利的药物开发特性的有前途的资源。除了次生代谢物具有被充分证实的重要作用外，中心代谢和信号事件衍生的内源性小分子与代谢物-蛋白质相互作用独特，因此成为很好的药物候选者。在本篇简短的综述中，我们突出了自然产物的价值，讨论了包括代谢组学工具、化学蛋白质组学和基于人工智能的计算平台在内的最新科学和技术进展，并探讨了克服目前自然产物驱动的药物发现领域的挑战的潜在策略。 ©2022作者。该文章由Informa UK Limited，交易名称为Taylor＆Francis Group发表。

Natural products (NPs) have greatly contributed to the development of novel treatments for human diseases such as cancer, metabolic disorders, and infections. Compared to synthetic chemical compounds, primary and secondary metabolites from medicinal plants, fungi, microorganisms, and our bodies are promising resources with immense chemical diversity and favorable properties for drug development. In addition to the well-validated significance of secondary metabolites, endogenous small molecules derived from central metabolism and signaling events have shown great potential as drug candidates due to their unique metabolite-protein interactions. In this short review, we highlight the values of NPs, discuss recent scientific and technological advances including metabolomics tools, chemoproteomics approaches, and artificial intelligence-based computation platforms, and explore potential strategies to overcome the current challenges in NP-driven drug discovery.© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.